Users will be able to sync data from their Eversense CGM directly into Glooko’s platform and view historical glucose trends, as well as receive real-time readings from their Eversense mobile app, according to Senseonics.
Doctors and other healthcare professionals will also be able to access their patients’ data in Glooko’s Population Tracker.
The companies expect that the Eversense/Glooko integration will take place by the end of the year. Senseonics and Glooko said they plan to use the insights they glean from this partnership to help them as they expand into insulin titration and decision support tools.
“With this integration, users can consolidate their glucose data with insulin, meals, medication and exercise to help them see glycemic patterns more readily. Glooko allows our users to take full advantage of both companies’ platforms and the large amount of data from our Eversense and Eversense XL systems,” Senseonics president & CEO Tim Goodnow said in prepared remarks.
“We are thrilled to add Senseonics’ breakthrough Eversense and Eversense XL CGM data to our platform so that people with diabetes and clinicians can access this valuable data in context in our reports online and via mobile,” Glooko CEO Russ Johannesson added. “Our cloud integration with Senseonics gives users easy access to their glucose data from the sensor, enabling them to make decisions based on their glucose patterns.”
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.